TTC and USciences Sponsors "The State of Clinical Development Costs" Conference in Philadelphia
On January 11-12, 2011 TTC, llc, provider of industry-wide cost benchmarking tools, and the University of the Sciences in Philadelphia (USciences) sponsored the “The State of Clinical Development Costs" conference. Drawing 80 decision makers and specialists from a host of pharmaceutical, biotechnology and medical device companies, and CROs, the 2-day event included two keynote addresses, one by David Fairbrother, Director of Clinical Budgeting at Forest Laboratories, and Hani Zaki, Senior Vice President of PRA International, who spoke on “Future Challenges of Clinical Development; a View from the CRO."
The conference highlighted evidenced based decision-making and research findings. Proceeds from the conference are to be devoted to pursue evidence based research issues that arose during the session. TTC “State of Clinical Development” conference panels addressed a range of topics;“Effective Budgeting and Management of CRO Costs,” “Standard of Care Costs in Clinical Trials, and “Compliance and Fair Market,” “Clinical Trial Costs in Emerging Geographies,” and “Standard of Care Costs in Clinical Trials.”
Additional presentations were given by Dr. Patricia R. Audet on "Productivity and Costs in Today's HealthCare Arena," and by Dr. Laurence Poli of TTC on how CROs and sponsor companies can work together more efficiently.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
